TXG Stock - 10x Genomics, Inc.
Unlock GoAI Insights for TXG
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $610.78M | $618.73M | $516.41M | $490.49M | $298.85M |
| Gross Profit | $414.48M | $409.31M | $396.02M | $416.40M | $240.38M |
| Gross Margin | 67.9% | 66.2% | 76.7% | 84.9% | 80.4% |
| Operating Income | $-194,559,000 | $-265,329,000 | $-167,944,000 | $-52,913,000 | $-85,324,000 |
| Net Income | $-182,627,000 | $-255,099,000 | $-166,000,000 | $-58,223,000 | $-542,731,000 |
| Net Margin | -29.9% | -41.2% | -32.1% | -11.9% | -181.6% |
| EPS | $-1.52 | $-2.18 | $-1.46 | $-0.53 | $-5.37 |
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Visit WebsiteEarnings History & Surprises
TXGEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 11, 2026 | $-0.20 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.07 | $-0.22 | -214.3% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.35 | $0.28 | +180.0% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.45 | $-0.36 | +20.0% | ✓ BEAT |
Q1 2025 | Feb 12, 2025 | $-0.29 | $-0.40 | -37.9% | ✗ MISS |
Q4 2024 | Oct 29, 2024 | $-0.34 | $-0.30 | +11.8% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.47 | $-0.32 | +31.9% | ✓ BEAT |
Q2 2024 | Apr 30, 2024 | $-0.46 | $-0.50 | -8.7% | ✗ MISS |
Q1 2024 | Feb 15, 2024 | $-0.36 | $-0.41 | -13.9% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.45 | $-0.51 | -13.3% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-0.39 | $-0.53 | -35.9% | ✗ MISS |
Q2 2023 | May 3, 2023 | $-0.38 | $-0.44 | -15.8% | ✗ MISS |
Q1 2023 | Feb 15, 2023 | $-0.29 | $-0.15 | +48.3% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $-0.45 | $-0.37 | +17.8% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.40 | $-0.57 | -42.5% | ✗ MISS |
Q2 2022 | May 4, 2022 | $-0.37 | $-0.38 | -2.7% | ✗ MISS |
Q1 2022 | Feb 16, 2022 | $-0.06 | $-0.16 | -166.7% | ✗ MISS |
Q4 2021 | Nov 3, 2021 | $-0.18 | $-0.15 | +16.7% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $-0.26 | $-0.10 | +61.5% | ✓ BEAT |
Latest News
Frequently Asked Questions about TXG
What is TXG's current stock price?
What is the analyst price target for TXG?
What sector is 10x Genomics, Inc. in?
What is TXG's market cap?
Does TXG pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to TXG for comparison